7Baggers

Zentalis Pharmaceuticals, Inc
(NASDAQ:ZNTL) 

ZNTL stock logo

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical ...

Full Time Employees: 110
CEO: Anthony Y. Sun  
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 
                             
      operating expenses
    		                         
      research and development
    		28,716,000 29,488,000 22,950,000 27,610,000 27,247,000 32,973,000 36,824,000 48,386,000 49,585,000 51,557,000 46,765,000 42,684,000 48,584,000 40,616,000 42,181,000 43,825,000 46,112,000 38,439,000 53,998,000 44,770,000 38,394,000 29,521,000 24,670,000 17,452,000 13,258,000 
      general and administrative
    		9,139,000 7,905,000 10,784,000 8,448,000 10,580,000 40,005,000 14,608,000 16,762,000 15,740,000 16,365,000 15,953,000 15,664,000 16,369,000 11,138,000 12,012,000 19,636,000 11,767,000 9,754,000 8,872,000 10,362,000 11,953,000 10,724,000 10,097,000 9,924,000 3,141,000 
      restructuring
    		    7,796,000                     
      total operating expenses
    		37,855,000 37,393,000 33,734,000 36,058,000 45,623,000 76,714,000 51,432,000 65,148,000 65,325,000 67,922,000 62,718,000 103,916,000 64,953,000 51,754,000 54,193,000 63,461,000 57,879,000 48,193,000 62,870,000 55,132,000 50,347,000 40,245,000 34,767,000 27,376,000 16,399,000 
      income from operations
    		-37,855,000 -37,393,000 -33,734,000 -36,058,000 -45,623,000 -49,849,000 -51,432,000 -65,148,000 -24,765,000                 
      yoy
    		-17.03% -24.99% -34.41% -44.65% 84.22%                     
      qoq
    		1.24% 10.85% -6.45% -20.97% -8.48% -3.08% -21.05% 163.06%                  
      other income
    		                         
      investment and other income
    		2,623,000 2,619,000 7,043,000 9,184,000 -2,656,000 2,172,000 11,247,000 -22,863,000 34,948,000 6,848,000 7,209,000 4,451,000 4,109,000 3,232,000 1,905,000 424,000 426,000 88,000 99,000 115,000  315,000 120,000 84,000  
      net loss before income taxes
    		-35,232,000 -34,774,000 -26,691,000 -26,874,000  -47,677,000 -40,185,000 -88,011,000  -61,074,000 -55,509,000 -99,465,000 -60,844,000 -48,522,000 -52,288,000 -63,037,000 -57,453,000 -48,105,000 -11,189,000 -55,017,000 -50,248,000 -39,930,000 -34,647,000 -27,292,000 -16,235,000 
      income tax expense
    		120,000     -205,000 -27,000 266,000 143,000 -116,500 31,000 -605,000 108,000 -360,000 -159,000 17,000 33,000 159,000 -697,000 45,000 196,000 426,000 18,000   
      net income
    		-35,352,000 -35,216,000 -26,691,000 -26,874,000 -48,279,000 -47,472,000 -40,158,000 -88,277,000 10,040,000 -60,939,000 -55,540,000 -112,564,000 -63,262,000 -54,984,000 -54,500,000 -68,392,000 -59,237,000 -50,095,000 -10,492,000 -55,062,000 -50,444,000 -40,356,000 -34,665,000 -27,292,000 -16,235,000 
      yoy
    		-26.78% -25.82% -33.54% -69.56% -580.87% -22.10% -27.70% -21.58% -115.87% 10.83% 1.91% 64.59% 6.79% 9.76% 419.44% 24.21% 17.43% 24.13% -69.73% 101.75% 210.71%     
      qoq
    		0.39% 31.94% -0.68% -44.34% 1.70% 18.21% -54.51% -979.25% -116.48% 9.72% -50.66% 77.93% 15.06% 0.89% -20.31% 15.45% 18.25% 377.46% -80.95% 9.15% 25.00% 16.42% 27.02% 68.11%  
      net loss per common share outstanding, basic and diluted
    		-500 -490 -370 -370  -660 -560 -1,240  -830 -790 -1,850 -1,070 -920 -960 -1,340 -1,310 -1,130 -90 -1,340 -1,240 -980 -910 -780  
      common shares used in computing net loss per share, basic and diluted
    		70,264 -69 72,139 71,992  63 71,111 71,040  1,808 70,612 60,790 59,277 1,759 56,807 51,117 45,244 10,479.5 44,609 40,738      
      license revenue
    		     10,140,000   40,560,000                 
      net loss attributable to noncontrolling interests
    		        -28,000 -22,000 -12,000 -37,000 -43,000 -13,000 -99,000 -35,000 -160,000 -36,000 -6,301,000 -488,000 -543,000 -53,000 -110,000 -435,000 -109,000 
      net loss attributable to zentalis
    		 -35,216,000 -26,691,000 -26,874,000  -47,472,000 -40,158,000 -88,277,000  -60,917,000 -55,528,000 -112,527,000 -63,219,000 -54,971,000 -54,401,000 -68,357,000 -59,077,000 -50,059,000 -4,191,000 -54,574,000 -49,901,000 -40,303,000 -34,555,000 -26,857,000  
      net income before income taxes
    		    -48,279,000    10,183,000                 
      net income attributable to zentalis
    		    -48,279,000    10,068,000                 
      earnings per share
    		                         
      basic
    		    -0.67    0.14                 
      diluted
    		    -0.67    0.14                 
      weighted-average common shares outstanding
    		                         
      basic
    		    71,678    70,898                 
      diluted
    		    71,678    71,192                 
      zentera in-process research and development
    		           45,568,000              
      loss on equity method investment
    		           13,704,000 2,310,000 6,822,000 2,371,000 5,338,000 1,751,000         
      operating income
    		         -57,896,750 -62,718,000 -103,916,000 -64,953,000 -43,883,250 -54,193,000 -63,461,000 -57,879,000 -42,087,250 -62,870,000 -55,132,000 -50,347,000 -40,245,000 -34,767,000 -27,376,000 -16,399,000 
      gain on deconsolidation of zentera
    		                  51,582,000       
      interest income
    		                    143,000    164,000 
      other expense
    		                    -44,000     
      net loss per class a common unit outstanding, basic and diluted
    		                        -2,880 
      common shares/units used in computing net loss per share/class a common unit, basic and diluted
    		                    40,359 3,970 37,959 34,353  
      net loss attributable to zentalis pharmaceuticals, llc
    		                        -16,126,000 
      units used in computing net loss per class a common unit, basic and diluted
    		                        5,601,000 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 
                               
        assets
      		                         
        current assets
      		                         
        cash and cash equivalents
      		31,930,000 35,995,000 39,072,000 37,599,000 41,929,000 33,901,000 41,320,000 36,976,000 37,616,000 28,038,000 110,751,000 266,558,000 36,280,000 43,069,000 42,551,000 55,143,000 30,572,000 59,714,000 40,807,000 49,170,000 28,996,000 54,951,000 92,552,000 96,016,000 63,650,000 
        marketable debt securities, available-for-sale
      		179,828,000                         
        prepaid expenses and other current assets
      		6,338,000 7,298,000 7,605,000 8,165,000 10,429,000 9,982,000 9,018,000 13,231,000 14,822,000 13,799,000 11,627,000 10,943,000 17,707,000 14,562,000 12,164,000 12,405,000 11,670,000 10,636,000 10,423,000 8,301,000 7,725,000 6,182,000 5,178,000 5,217,000 2,220,000 
        total current assets
      		218,096,000 253,191,000 288,302,000 311,596,000 342,882,000 386,066,000 400,270,000 439,616,000 503,806,000 496,718,000 528,264,000 563,929,000 410,226,000 451,933,000 433,890,000 467,626,000 301,282,000 350,770,000 377,565,000 259,449,000 306,354,000 345,104,000 372,736,000 238,481,000 66,009,000 
        property and equipment
      		2,653,000 2,770,000 2,927,000 3,087,000 3,247,000 4,699,000 5,016,000 5,337,000 5,679,000 5,819,000 6,393,000 6,650,000 6,880,000 7,705,000 8,027,000 8,218,000 8,480,000 8,148,000 4,698,000 2,251,000 1,508,000 1,099,000 471,000 481,000 519,000 
        operating lease right-of-use assets
      		25,595,000 26,271,000 30,188,000 31,175,000 31,925,000 32,528,000 33,403,000 33,474,000 34,726,000 35,916,000 36,184,000 36,584,000 37,475,000 42,373,000 42,646,000 43,305,000 43,644,000 44,691,000 693,000 1,195,000 1,901,000 2,520,000 1,925,000 2,090,000 2,276,000 
        prepaid expenses and other assets
      		4,095,000 4,108,000 3,206,000 3,222,000 3,340,000 4,417,000 5,609,000 6,836,000 6,851,000 6,818,000 8,511,000 7,918,000 9,495,000 9,723,000 10,232,000 11,938,000 10,164,000 7,040,000 6,042,000 4,794,000 2,790,000 2,976,000 4,245,000 3,218,000 2,353,000 
        restricted cash
      		2,627,000 2,627,000 2,627,000 2,627,000 2,627,000 2,627,000 2,627,000 2,681,000 2,681,000 2,681,000 2,627,000 2,627,000 2,627,000    243,000 243,000 243,000 243,000 3,264,000 1,320,000 1,320,000 411,000 411,000 
        total assets
      		253,066,000 288,967,000 327,250,000 351,707,000 384,021,000 430,337,000 450,661,000 491,680,000 557,479,000 551,688,000 585,715,000 621,444,000 489,342,000 539,310,000 529,193,000 567,856,000 405,677,000 454,507,000 435,081,000 283,962,000 328,353,000 365,555,000 393,233,000 257,217,000 87,629,000 
        liabilities and stockholders’ equity
      		                         
        current liabilities
      		                         
        accounts payable
      		7,378,000 7,208,000 7,031,000 3,719,000 7,769,000 7,438,000 8,202,000 20,440,000 10,502,000 14,926,000 14,264,000 12,305,000 12,818,000 11,247,000 9,820,000 12,041,000 13,163,000 11,590,000 8,046,000 8,273,000 8,337,000 8,661,000 5,437,000 4,217,000 7,019,000 
        accrued expenses
      		27,858,000 29,351,000 30,137,000 35,303,000 41,661,000 45,287,000 46,675,000 46,252,000 44,296,000 54,441,000 44,654,000 39,454,000 43,540,000 45,400,000 44,241,000 36,595,000 30,322,000 32,354,000 31,369,000 25,304,000 24,460,000 19,940,000 18,469,000 11,350,000 9,920,000 
        total current liabilities
      		35,236,000 36,559,000 37,168,000 39,022,000 49,430,000 52,725,000 54,877,000 66,692,000 54,798,000 69,367,000 58,918,000 51,759,000 56,358,000 56,647,000 54,061,000 48,636,000 43,485,000 43,944,000 39,415,000 33,577,000 32,797,000 28,601,000 23,906,000 15,567,000 16,939,000 
        long-term lease liability
      		34,650,000 35,704,000 36,708,000 37,690,000 38,651,000 39,577,000 40,457,000 41,318,000 42,616,000 43,150,000 43,266,000 44,027,000 44,771,000 45,166,000    44,459,000        
        other long-term liabilities
      		500,000 500,000 500,000 500,000 558,000 849,000 996,000 1,089,000 1,294,000 1,780,000 1,634,000 2,376,000 1,792,000 2,620,000 45,169,000 45,072,000 44,978,000   296,000 438,000 1,097,000 1,031,000 1,262,000 1,484,000 
        total liabilities
      		70,386,000 72,763,000 74,376,000 77,212,000 88,639,000 93,151,000 96,330,000 109,099,000 98,708,000 114,297,000 103,818,000 98,162,000 103,677,000 105,286,000 100,455,000 95,033,000 90,011,000 90,025,000 41,085,000 36,353,000 35,715,000 32,178,000 27,400,000 19,292,000 20,886,000 
        commitments and contingencies
      		                         
        equity
      		                         
        preferred stock, 0.001 par value...
      		                         
        common stock, 0.001 par value...
      		71,000 69,000 72,000 72,000 72,000 71,000 71,000 71,000 70,000 70,000 70,000 70,000 59,000 59,000 57,000 57,000 46,000 45,000 45,000 41,000 41,000 41,000 41,000 36,000  
        additional paid-in capital
      		1,409,466,000 1,407,394,000 1,408,855,000 1,403,912,000 1,397,626,000 1,390,952,000 1,359,589,000 1,349,135,000 1,336,416,000 1,323,576,000 1,309,696,000 1,295,520,000 1,045,568,000 1,031,462,000 972,111,000 961,205,000 734,997,000 723,593,000 702,855,000 529,019,000 519,030,000 509,339,000 501,522,000 339,160,000  
        accumulated other comprehensive income
      		-50,000 196,000 186,000 59,000 358,000 558,000 1,594,000 140,000 773,000 2,194,000        -125,000 32,000 94,000 50,000 36,000 23,000 4,000  
        accumulated deficit
      		-1,226,807,000 -1,191,455,000 -1,156,239,000 -1,129,548,000 -1,102,674,000 -1,054,395,000 -1,006,923,000 -966,765,000 -878,488,000 -888,556,000 -827,639,000 -772,111,000 -659,584,000 -596,365,000 -541,394,000 -486,993,000 -418,636,000 -359,559,000 -309,500,000 -305,309,000 -250,735,000 -200,834,000 -160,531,000 -125,976,000 -99,119,000 
        total stockholders’ equity
      		182,680,000  252,874,000 274,495,000 295,382,000  354,331,000 382,581,000 458,771,000  481,768,000 523,141,000 385,487,000  428,504,000 472,490,000 315,298,000  393,432,000 223,845,000      
        total liabilities and stockholders’ equity
      		253,066,000  327,250,000 351,707,000 384,021,000  450,661,000 491,680,000 557,479,000  585,715,000 621,444,000 489,342,000  529,193,000 567,856,000 405,677,000  435,081,000 283,962,000      
        marketable debt securities, available for sale
      		 209,898,000    318,009,000                    
        marketable equity securities
      		  2,406,000 16,791,000 12,151,000 19,174,000                    
        contracts receivable
      		     5,000,000                    
        liabilities and stockholders' equity
      		                         
        total stockholders' equity
      		 216,204,000    337,186,000    437,284,000    433,803,000    363,954,000   268,386,000     
        total liabilities and stockholders' equity
      		 288,967,000    430,337,000    551,688,000    539,310,000    454,507,000        
        marketable securities, available-for-sale
      		  239,219,000 249,041,000 278,373,000  349,932,000 389,409,000 451,368,000  405,886,000 286,428,000 356,239,000  379,175,000 400,078,000 258,797,000  325,984,000 201,730,000   274,884,000 137,175,000  
        goodwill
      		      3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 3,736,000 
        noncontrolling interests
      		         107,000 129,000 141,000 178,000 221,000 234,000 333,000 368,000 528,000 564,000 23,764,000 24,252,000 24,795,000 24,778,000 24,701,000 6,712,000 
        total equity
      		     337,186,000 354,331,000 382,581,000 458,771,000 437,391,000 481,897,000 523,282,000 385,665,000 434,024,000 428,738,000 472,823,000 315,666,000 364,482,000 393,996,000 247,609,000 292,638,000 333,377,000 365,833,000 237,925,000  
        marketable securities, available for sale
      		         454,881,000    394,302,000    280,173,000   269,385,000 283,554,000    
        investment in zentera therapeutics
      		            18,903,000 21,213,000 28,035,000 30,406,000 35,744,000 37,495,000 39,326,000       
        deferred tax liability
      		            756,000 853,000 1,225,000 1,325,000 1,548,000 1,622,000 1,670,000 2,480,000 2,480,000 2,480,000 2,463,000 2,463,000 2,463,000 
        accumulated other comprehensive loss
      		          -359,000 -338,000 -556,000 -1,353,000 -2,270,000 -1,779,000 -1,109,000         
        accounts receivable from government grants
      		                 4,000 108,000 5,000 248,000 417,000 122,000 73,000 139,000 
        in-process research and development
      		                   8,800,000 8,800,000 8,800,000 8,800,000 8,800,000 8,800,000 
        deferred financing costs
      		                   716,000     3,525,000 
        liabilities, convertible preferred units and equity
      		                         
        total liabilities and equity
      		                    328,353,000     
        convertible preferred units; redemption value of 146,944 at december 31, 2019
      		                         
        class a common units; 20,000,000 units authorized at december 31, 2019; 5,601,478 units issued and outstanding at december 31, 2019
      		                         
        class b common units 3,458,522 units authorized at december 31, 2019; 2,670,668 units issued and outstanding at december 31, 2019
      		                         
        total stockholders' equity/members'
      		                     308,582,000    
        total liabilities, convertible preferred units and equity
      		                     365,555,000 393,233,000 257,217,000  
        liabilities, convertible preferred units and equity/
      		                         
        convertible preferred units; redemption value of 146,944,000 at december 31, 2019
      		                         
        class a common units; 20,000,000 units authorized; 5,601,478 units issued and outstanding at december 31, 2019
      		                         
        class b common units, 3,458,522 units authorized; 2,670,668 units issued and outstanding at december 31, 2019
      		                         
        total stockholders’ equity/members’
      		                      341,055,000 213,224,000  
        liabilities, convertible preferred units and deficit
      		                         
        convertible preferred units; redemption value of 162,120,000 and 146,944,000 at march 31, 2020 and december 31, 2019, respectively
      		                        155,934,000 
        class a common units; 20,000,000 units authorized at march 31, 2020 and december 31, 2019; 5,601,478 units issued and outstanding at march 31, 2020 and december 31, 2019
      		                        709,000 
        class b common units, 3,458,522 units authorized at march 31, 2020 and december 31, 2019; 2,607,309 and 2,670,668 units issued and outstanding at march 31, 2020 and december 31, 2019, respectively
      		                        2,507,000 
        total zentalis pharmaceuticals, llc members’ deficit
      		                        -95,903,000 
        total deficit
      		                        -89,191,000 
        total liabilities, convertible preferred units and deficit
      		                        87,629,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 
                                 
          operating activities:
        		                         
          net loss
        		-35,352,000                         
          adjustments to reconcile net loss to net cash from operating activities:
        		                         
          depreciation and amortization
        		151,000 157,000 160,000 160,000 262,000 317,000 321,000 327,000 324,000 337,000 348,000 344,000 360,000 359,000 375,000 348,000 344,000 209,000 137,000 119,000 79,000 33,000 51,000 38,000 38,000 
          fixed asset impairment
        		  0 0 1,152,000                     
          share-based compensation
        		3,197,000 3,122,000 4,828,000 6,286,000 6,486,000 31,363,000 10,362,000 12,711,000 12,833,000 13,880,000 13,867,000 13,342,000 13,733,000 9,612,000 10,317,000 16,764,000 10,147,000 8,471,000 7,656,000 9,919,000 9,691,000 7,887,000 7,249,000 7,681,000 329,000 
          non-cash recognized loss on mark-to-market of equity securities
        		                         
          accretion of discounts on marketable securities
        		-224,000 -431,000 -517,000 -781,000 -1,034,000 -1,397,000 -1,645,000                   
          changes in operating assets and liabilities:
        		                         
          contracts receivable
        		  0 0 5,000,000                     
          prepaid expenses and other assets
        		973,000 -698,000 679,000 2,349,000 663,000 228,000 5,440,000 1,606,000 -1,056,000 -479,000 -1,277,000 -1,005,000 -2,917,000 -1,885,000 1,943,000 -2,509,000 -4,154,000 -815,000 5,633,000 -2,580,000 -1,357,000 265,000 -988,000 -3,746,000 -1,050,000 
          accounts payable and accrued liabilities
        		-1,451,000 -733,000 -1,976,000 -10,584,000 -4,023,000 -2,562,000 -12,008,000 11,797,000 -15,249,000 10,397,000 6,327,000 -4,394,000 -1,411,000 5,050,000 6,452,000 4,599,000 -574,000 1,606,000 7,472,000 1,531,000 3,307,000 5,258,000 7,837,000 1,159,000 53,000 
          operating lease right-of-use assets and liabilities
        		-250,000 53,000 127,000 -93,000 114,000 258,000 -690,000   350,000 -271,000 235,000 309,000 822,000 1,230,000 897,000 1,381,000 1,472,000 -392,000 -515,000 782,000 -498,000 -158,000 -4,000 -7,000 
          net cash from operating activities
        		-32,956,000 -30,940,000 -26,963,000 -34,708,000 -32,636,000 -39,702,000 -44,045,000 -35,139,000 -51,974,000 -40,599,000 -38,665,000 -79,275,000 -49,283,000 -37,329,000 -33,199,000 -43,027,000 -50,196,000 -37,021,000 -33,490,000 -46,113,000 -37,469,000 -27,357,000 -20,564,000 -22,033,000 -16,871,000 
          capital expenditures
        		-34,000 0 0 0  0 0 -181,000 -40,000 -173,000 -91,000 0  -160,000 -1,660,000 -278,000 -450,000 -2,191,000 -2,661,000 -819,000 -369,000 -661,000 -41,000 -25,000 -6,000 
          free cash flows
        		-32,990,000 -30,940,000 -26,963,000 -34,708,000  -39,702,000 -44,045,000 -35,320,000 -52,014,000 -40,772,000 -38,756,000 -79,275,000  -37,489,000 -34,859,000 -43,305,000 -50,646,000 -39,212,000 -36,151,000 -46,932,000 -37,838,000 -28,018,000 -20,605,000 -22,058,000 -16,877,000 
          investing activities:
        		                         
          purchases of marketable securities
        		-29,952,000  -49,534,000 -40,186,000 -19,530,000  -59,236,000 -19,394,000 -10,115,000 -95,987,000 -264,110,000 -125,206,000 -63,879,000 -125,984,000 -129,601,000 -198,322,000 -79,254,000 -83,223,000 -202,473,000 -23,378,000 -54,434,000 -96,899,000 -166,849,000   
          proceeds from maturities of marketable securities
        		60,000,000  60,000,000 70,000,000 60,000,000  74,000,000 54,000,000 71,700,000 54,100,000 146,750,000 198,457,000 106,000,000 114,250,000 151,279,000 56,500,000 99,500,000 128,681,000 78,011,000 90,800,000 68,328,000 87,910,000    
          proceeds from sale of property and equipment
        		 129,000 0 564,000 5,000 0 0                   
          purchases of property and equipment
        		-34,000     0 0 -181,000 -40,000 -173,000 -91,000   -160,000 -1,660,000 -278,000 -450,000 -2,191,000 -2,661,000 -819,000 -436,000 -661,000 -41,000 -25,000 -31,000 
          net cash from investing activities
        		30,014,000 32,449,000 28,321,000 30,378,000 40,475,000 32,283,000 48,243,000 34,490,000 61,545,000 -42,060,000 -117,451,000 72,932,000 42,121,000 -11,894,000 20,018,000 -142,100,000 19,796,000 43,267,000    -9,650,000 -137,890,000 -137,261,000 -31,000 
          financing activities:
        		                         
          proceeds from issuance of common stock under equity incentive plans
        		331,000 0 115,000 0 189,000 0 92,000 9,000 248,000 0 309,000 941,000 373,000 1,116,000 589,000 158,000 1,258,000 3,663,000        
          net-settlement of restricted stock unit vesting
        		-1,454,000     0 0 0 -241,000                 
          net cash from financing activities
        		-1,123,000 -4,586,000 115,000 0 189,000 0 92,000 9,000 7,000 0 309,000 236,621,000 373,000 49,741,000 589,000 209,455,000 1,258,000 12,267,000    -594,000 155,899,000 191,660,000 13,474,000 
          net increase in cash, cash equivalents and restricted cash
        		-4,065,000 -3,077,000 1,473,000 -4,330,000 8,028,000 -7,419,000 4,290,000 -640,000 9,578,000 -82,659,000 -155,807,000      -29,142,000 18,513,000 -8,363,000    -2,555,000   
          cash, cash equivalents and restricted cash at beginning of period
        		38,622,000  0 0 36,528,000  0 0 30,719,000  0 0 45,696,000  0 0 62,584,000  0    0   
          cash, cash equivalents and restricted cash at end of period
        		34,557,000  1,473,000 -4,330,000 44,556,000  4,290,000 -640,000 40,297,000  -155,807,000 230,278,000 38,907,000  -12,592,000 24,328,000 33,442,000  -8,363,000    -2,555,000   
          operating lease right-of-use and fixed asset impairment
        		                         
          noncash consideration portion of zentera in-process research and development
        		         0 0               
          goodwill impairment
        		                         
          loss on disposal of equipment
        		     0 0 53,000 -66,000 410,000        0 0 0 15,000     
          non-cash impact of revenues from licensing and sales of intellectual property
        		                         
          non-cash recognized mark-to-market of equity securities
        		     2,692,000 -5,667,000 28,916,000 -31,169,000                 
          loss on equity method investment
        		         0 0 13,704,000 2,310,000 6,822,000 2,371,000 5,338,000 1,751,000         
          deferred income taxes
        		         0 0 -756,000 -97,000             
          deconsolidation of kalyra
        		     0 0 0 -79,000                 
          accounts receivable
        		                 104,000 -103,000 243,000 169,000 -295,000 -49,000 66,000 1,000 
          purchases of marketable debt securities
        		                         
          proceeds from maturities of marketable debt securities
        		                         
          proceeds from sale of marketable equity securities
        		 2,558,000                        
          proceeds from issuance of common stock
        		         0 0   48,625,000 0   9,750,000    -594,000    
          repurchase of common stock
        		                         
          cash, cash equivalents and restricted cash at beginning of year
        		                    56,271,000    67,489,000 
          cash, cash equivalents and restricted cash at end of year
        		                    32,260,000    64,061,000 
          supplemental disclosure of cash flow information:
        		                         
          income taxes paid
        		                         
          supplemental disclosure of non-cash investing and financing activities:
        		                         
          right-of-use assets obtained in exchange for operating lease liabilities
        		                         
          consolidated net loss
        		  -26,691,000    -40,158,000    -55,540,000 -112,564,000 -63,262,000  -54,500,000 -68,392,000 -59,237,000  -10,492,000 -55,062,000 -50,444,000 -40,356,000 -34,665,000 -27,292,000 -16,235,000 
          gain on disposal of equipment
        		  -103,000                       
          non-cash impact of license revenue
        		      0 0 -25,560,000                 
          non-cash recognized gain on mark-to-market of equity securities
        		                         
          deconsolidation of variable interest entity
        		                         
          non-cash recognized loss mark-to-market of equity securities
        		   -4,640,000 7,023,000                     
          consolidated net income
        		    -48,279,000    10,040,000                 
          operating lease right-of-use asset and fixed asset impairment
        		        772,000 0 0 0 4,953,000             
          proceeds from sale of marketable securities
        		                         
          adjustments to reconcile net income to net cash from operating activities:
        		                         
          (accretion of discounts)/amortization of premiums on marketable securities
        		        -2,764,000 -4,555,000 -2,119,000 -3,222,000 -3,261,000             
          ipr&d impairment
        		                 0        
          recognized tax gain on ipr&d impairment
        		                 0        
          gain on deconsolidation of zentera, net of tax
        		                 0        
          deconsolidation of zentera cash
        		                 0        
          accrued capital expenditures
        		            209,000   -135,000 226,000         
          net decrease in cash, cash equivalents and restricted cash
        		            -6,789,000  -12,592,000           
          proceeds from issuance of common stock in initial public offering
        		                     0 0   
          contributions from noncontrolling interest owners
        		                     0 0   
          proceeds from the issuance of series c convertible preferred units
        		                     0 0 0 14,228,000 
          amortization of premiums on marketable securities
        		              -1,266,000 -129,000 146,000 196,000 191,000 232,000 289,000 332,000 159,000   
          deferred financing costs
        		                        -754,000 
          accrued deferred financing costs
        		                         
          costs incurred in connection with initial public offering included in accounts payable and accrued expenses
        		                       -1,860,000 1,930,000 
          net cash from/used in investing activities
        		                   66,603,000 13,458,000     
          proceeds from exercise of stock options
        		                         
          net cash from/provided by financing activities
        		                         
          decrease in cash, cash equivalents and restricted cash
        		                    -24,011,000    -3,428,000 
          amounts accrued for purchases of property and equipment
        		                    67,000    25,000 
          increase in cash, cash equivalents and restricted cash
        		                         
          costs incurred in connection with equity offering included in accounts payable and accrued liabilities